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Intellectual property protection (IPR) in plant breeding encompasses two different systems: Plant 
Breeder’s Rights (PBR), a system of IPR specifically designed for plant varieties, and Patent rights, a 
generic (industrial) IPR system. Most (> 90%) of the patent applications regarding plants concern GM-
related inventions (i.e. transgenic plants). In the last two decades interest has risen in filing patent 
applications on products of conventional breeding as well. In the public discussion, traits involved have 
been named “native traits” as they usually were already naturally present as such in the progenitors of 
the novel plant line. Novelty lies in their recognition (or design of plant ideotypes) and/or combination 
into a useful trait in novel elite types of plants.  
This “quick scan” explored “native traits” in relation to patents in plant breeding using two approaches: 
1) an exploration of European patent applications potentially addressing conventional plant breeding, and 
2) interviews with stakeholders about their experiences with and opinion on IPR and “native traits”, in 
particular with regard to effects on access to genetic resources for breeding and innovation. The patent 
exploration was primarily aimed at obtaining an idea about the numbers of patents involving 
conventional breeding products, and about the crops and traits, and the claims concerned. Subsequently, 
we looked which questions could be raised with regard to access to plant genetic resources from the 
point of view of plant breeders/biologists. The exact scope of the claims can only be assessed by legal 
experts, but that was beyond the scope of this study.  
We used international patent classification codes (IPC) for plant-related inventions to find patent 
applications involving conventional plant breeding. Obtaining a comprehensive overview of patents did 
not succeed in this way. In the end, we also scanned patents from breeding companies in order to assess 
whether we had not missed patent applications. As this list of companies may not have been exhaustive, 
we still may have missed some patents. The main problem was distinguishing applications involving 
conventional breeding from the applications targeting genetic modification, i.e. transgenic plants, which 
represent the bulk of plant patents. For instance, applications involving genes may use them both for 
transformation and for generating markers to be used in introgressing the genes, thus conferring native 
traits to elite plant material using marker-assisted breeding (MAB). To classify applications correctly, we 
studied the claims in more detail, which is the normal practice in the patent field. Patent applications 
contain claims that may not be granted, but the number of granted patents was relatively small as most 
patent applications were still in the examination phase.  
The combined queries for European patent applications produced, up to the end of 2013, approximately 
400 applications with an expected relevance to conventional breeding products. The total number of 
plant biotechnology-related patents was in the order of 6100 (Winnink 2012). This number of 400 needs 
to be addressed with care as in the above search strategy patent applications may have been missed. 
For 2014 and 2015 82 new applications were found in a less exhaustive scan. Of the 400 found, 50 
applications apparently did not contain claims on plants and thus fell outside of the scan’s focus in so far 
this was aimed at possible effects on access to plant genetic resources. The majority of the patent 
applications encompassed arable and horticultural crops; only relatively few ornamental species were 
represented. In addition, a few medicinal crops were encountered. In view of the time available, 200 
applications could be reviewed in more detail for traits, crops and types of claims. The 200 applications 
studied in more detail included as much as possible vegetable crops, as they represent an important part 
of the activities of the Dutch breeding sector, plus other crops, covering as wide a variety of traits as 
possible, but due to the combination of a wide variation of traits and crops, figures can only be 
indicative. Claims in applications may not all be granted, but analysis of claims granted was only possible 
to a limited extent as most applications were still in the examination process.  
A steady growth in number of patent applications per year was observed from the 1980s up until the 
present day: of the 200 analysed, 5 were from the period of 1983 to 1992, 51 from 1993 to 2002 and 
144 from 2003 to 2012. The percentage granted was about 60% in the first two decades. No conclusions 
can be drawn for the last period of 2003 to 2012 as often the examination procedure was still ongoing. 
The traits involved are familiar with breeders efforts as known from scientific literature. The largest part 
of the applications concerned product quality (48%), encompassing traits for the grower (5%) and for 
the consumer (42%). For the grower, these are for instance improved yield and plant architectures 
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adapted to efficient harvesting. For the consumer, improved shelf life and taste or improved 
compositions with regard to (secondary) metabolites, such as glucosinolates and carotenoids in 
vegetables or fatty acids in oil crops like oilseed rape. Resistances against pathogens and pests had a 
share of 30%, among which against viruses, bacteria, fungi, oomycetes, nematodes and insects. Another 
part of the applications (15%) entailed traits related to F1 hybrid variety production, particularly male 
sterility (MS) and/or matching fertility restorers, the most common form being cytoplasmic MS (CMS).  
Patents could contain claims that were primarily “product-based”, i.e. referring to plants with a specified 
set of traits, or primarily “process-based”, i.e. a method by which a trait is introduced into (elite) plants 
(e.g. MAB). In the latter case, the products (plants) could be claimed as well, but that was not always 
the case, as mentioned above for the 50 applications not further examined for that reason. Methods 
could also be incorporated in the product claim, e.g. ‘obtainable by process x’, where they serve as a 
circumscription enabling reproducing the production of the plant (“product-by-process”). For patents 
granted, sometimes process claims were granted but the product claims not, or the other way round. 
The trend of the last two years seemed to be an increase in product-by-process claims, possibly as a 
consequence of the procedure on the Tomato and Broccoli cases at the Enlarged Board of Appeal of the 
EPO), who decided in 2015 that “essentially biological methods” of crossing and selection, including when 
supported by technical means such as marker-assisted breeding (MAB, see below), were not eligible for 
patenting. The products (plants) resulting from such a process of an “essentially biological” nature are 
eligible, if conforming to the usual patent law demands of novelty, inventiveness and applicability (G2/12 
& G2/13). 
“Native traits” is a term used in the public debate, but it is not a term used in patent applications or 
classifications. In order to obtain an overview of patent applications relevant with regard to native traits, 
we performed a broad search for applications containing claims related to conventional breeding 
products, that is, excluding genetic modification in the sense of plant transformation and producing 
transgenic plants that are outside the scope of this scan. Conventional breeding leads to varieties that 
breeders in Europe freely use for further breeding under PBR. Subsequently, we have looked at the 
relevance of the applications found for “native traits” by looking at the techniques used and the 
characteristics of the plants produced. With regard to the techniques used to produce the plants that 
carry the trait, the most basic is classical crossing and selection that are not eligible for patenting as 
mentioned above. Crossing and selection use genetic variation found in the crop species and cross-
compatible wild relatives, such as found in genebank collections. Cell fusion (somatic hybridization, 5 of 
the applications analysed) is a more advanced biotechnological method that may enable interspecific 
hybridizations that are very hard to achieve by other means. The plants produced will contain new 
combinations of naturally occurring traits that in some cases also could have been brought together by 
conventional crossing.  
Using mutagenesis (38 of the applications analysed), mutations are experimentally induced at higher 
frequency by treatments of a technical nature. Nevertheless, mutations arise as randomly as under 
natural conditions and desired traits are selected for by the same selection techniques as spontaneous 
mutations. In many cases, induced mutations in plant products cannot be distinguished from 
spontaneous mutations that are underlying natural variation (“native traits”) found in genetic resources. 
One needs to know the underlying methods by which the plants were generated, to determine whether 
the trait came from an existing plant source.  
The limited breeders exemption recently put in place enables the use of patented plant materials without 
permission from the patent holder, but plants developed still containing proprietary traits can only be 
marketed after obtaining a license. Thus, breeders will likely screen material for proprietary traits before 
using them in their own programmes. For assessing germplasm for the presence of proprietary traits, the 
traits descriptions in the claims will be analysed. These descriptions may be adapted according to 
assessments during the examination procedure. Descriptions could be based on phenotypic and/or 
genotypic characterizations. The seemingly most straightforward genotypic category, desirable alleles of 
specific genes identified, encompassed about an eighth of the patent applications analysed. A number of 
phenotypic traits may be part of basic measurements in normal breeding practice (e.g. fruit shape or 
colour). Traits that are described as, for instance, levels of a compound higher than a particular value or 
percentage, or as compared to a reference plant without the new trait, may be laborious to assess. 
However, they may be based on relatively simple modes of inheritance, i.e. loci or genes. On the other 
hand, disease resistance, often bred through R genes/loci, may also be based on combinations of QTLs 
 8 
 
(quantitative trait loci), thus more complex in the genotypic description. Complex cases where semi-
quantified descriptions were combined with polygenic/unknown or unspecified inheritance were found 
less commonly than with genes, loci or QTLs. Without a more detailed inquiry, it is difficult to estimate to 
what extent additional efforts would be required to identify proprietary traits when incorporating new 
germplasm into a breeding program.  
Overall, two fifths of the patent applications analysed encompassed marker-assisted breeding (MAB). 
DNA markers are an important innovation of the last two decades and have increased the efficiency of 
introducing new traits significantly. In the first instance, the necessary investment to develop markers 
meant an incentive for strengthening IP protection through patents, as methods cannot be protected 
through PBR. On the other hand, applying markers leads to higher efficiency of selection and thus also to 
cost reduction for developers of new varieties. At the same time, a competitor may now also be able to 
more quickly introduce a trait that was originally difficult to obtain, such as a pathogen resistance from a 
wild relative, into his own elite materials for developing new varieties.  
More than half of the patent applications involving MAB concerned introgression of QTL (quantitative trait 
loci). QTL are detected by a statistical association of a desired phenotypic trait with markers across a 
region on a genetic linkage map. This association described in the claims may extend to various numbers 
of markers in the chromosomal interval that are associated with the trait. Other desirable, yet 
undetected traits may be localized in or around the same chromosomal interval, since such chromosome 
intervals easily harbour large numbers (hundreds) of genes. In practice, hot spots of various types of 
QTLs may be found in genomes. This may raise the question whether any interference could occur with 
the use of such a genomic area for other traits when the proprietary QTL (i.e. the phenotypic trait) may 
still be identifiable. Due to its relative novelty, still few patents have been granted in this field.  
The interviews indicated that “native traits” were often regarded as part of a wider discussion about 
biotechnology, including transgenic plants, and access and benefit sharing of plant genetic resources. 
From the NGO’s point of view, the position of smallholder farming was pivotal. This included access to 
native traits conserved in landraces over generations, independently of whether they had become 
patentable by their definition and being engineered into elite cultivars. Among scientists, the freedom to 
operate or “open source” approach of PBR was appreciated, but in the end, the main point would be what 
would serve society at large the best, i.e. a responsible innovation process. Complex trait introgressions, 
particularly from wild species, were perceived by all companies as demanding large investments and thus 
providing a strong incentive for IPR protection. This is particularly so when they entail traits such as 
resistances that will quickly gain a large part of the seed market. Companies further varied in their 
preferences for IP protection of native traits through either PBR or patents. This depended on their 
appreciation of which IPR system gave the best balance between investments and revenues.  
Other aspects included transparency about which material contained proprietary traits and the advantage 
provided by PBR of “freedom to operate” with germplasm. Companies with a preference for patenting of 
particular traits sought a solution to some of the criticisms in increasing transparency. This could be 
achieved through e-licensing, i.e. offering proprietary materials on their websites with standard licensing 
terms available to all interested parties. Vegetable companies have been negotiating a licensing platform, 
which would also improve transparency about proprietary traits, the International Licensing Platform 
(ILP) Vegetable. In addition, the PINTO database initiative of ESA (European Seed Association) is filled 
by patent assignees on a voluntary basis and links patents to plant varieties marketed. The database 






The increasing pace of innovation in the plant breeding industry is reflected in an increased interest in 
the ways intellectual property can optimally be protected. Ideally, by IP protection the innovator should 
be able to obtain sufficient revenues to be able to sustain continued innovation. At the same time, 
optimal availability of genetic resources to breeders, both small and large companies, is essential for 
continued innovation. Intellectual property rights (IPR) in breeding have become an issue in discussions 
on the best ways to achieve global food security and these discussions also have extensions into 
considerations about ethics concerning living beings. Thus, IPR in breeding has caught attention of 
society at large.  
In IP protection in plant breeding, various systems play a role: trademarks, image rights, Plant Breeders’ 
Rights, and Patents. A separate system of Plant Patents for asexually propagated crops exists, amongst 
others, in the US, but that is not relevant to the situation in Europe. Plant Breeders’ Rights (PBR, enacted 
for sexually propagated crops under the Plant Variety Protection Act (PVPA) in the US), a system of IP 
protection specifically designed for plant varieties, and Patent rights, a generic (industrial, or ‘utility’ in 
the US to distinguish it from the Plant Patents mentioned above) IP protection system, are the main 
systems. The present use of both systems side by side is the subject of discussion in Europe. Briefly, for 
plant breeders’ rights (PBR), plant varieties are the basic unit of protection with regard to marketing and 
propagation. The varieties need to fulfil the conditions of novelty, and of distinctiveness, uniformity and 
stability (DUS). The protection is standardised, and it does not extend to the use of varieties in new 
breeding programmes, so germplasm in the form of varieties protected by PBR remains free for other 
breeders to use for breeding and commercialising new varieties (this is often referred to as the breeder’s 
exemption). Patent protection is for inventions that are defined as being novel (i.e. not part of the state 
of the art), inventive (or non-obvious), and industrially applicable. The applicant needs to describe what 
the invention entails, i.e. formulate claims defining for which elements of the invention protection is 
desired. These claims may include methods of production or use, and the products made using the 
invention. Patents also contain a detailed description of the invention, which can be used by third parties 
for further innovation and development. However, direct use of the patented material is only allowed 
with permission (a license) from the patent holder, except for a research exemption, which entails 
testing for the usefulness or presence of the invention, and a recently enacted limited breeders’ 
exemption, which is only applicable in some European countries (see below).  
Plant varieties can be protected through PBR, but they are not eligible for industrial patent protection in 
Europe. In contrast, plants that contain an invention that is industrially applicable and can be introduced 
and perform its function in other plants or plant varieties, are eligible for patenting in Europe. Using such 
plants freely in further breeding, as is allowed in the case of protection by PBR, is possible only when an 
explicit exemption is included in patent law. This has been the subject of discussions in Europe for many 
years. France, Germany and Switzerland have a limited exemption for plant breeding, which was recently 
followed by the EU in its ‘unitary patent’ and The Netherlands (33 365 (R1987) “Wijziging van artikel 53b 
van de Rijksoctrooiwet 1995 in verband met de invoering van een beperkte veredelingsvrijstelling”). With 
the introduction of the limited exemption for plant breeding, breeders are allowed to use patented 
biological material for breeding and developing new plant varieties. For commercialization of the newly 
bred variety, however, a license of the patent holder is required when the proprietary trait is still present 
in the plant material. There are ongoing discussions about a broad exemption, in which also 
commercialization would be allowed.  
In both the TRIPs Agreement and European patent law (the European Patent Convention (EPC) and the 
EU Directive 98/44/EC on the legal protection of biotechnological inventions), an exception (exclusion) 
exists with relevance to plant breeding. That is the exception for “essentially biological processes for the 
production of plants or animals”, which are not eligible for patenting (Article 53(b) EPC and Article 4(1)b 
98/44/EC). “Essentially biological processes” refer to the basic breeding methods of crossing and 
selection (Rule 26(5) EPC and Article 2(2) 98/44/EC). These issues around the parallel existence of PBR 
and patents have been reviewed by Louwaars et al. (2009) and the ongoing discussion between 
stakeholders about how to handle PBR and industrial patents in plant breeding in practice in the 
Netherlands was the topic of the Trojan report (2012).  
The patentability of conventional plant breeding products with regard to the interpretation of this 
exception (exclusion) was the subject of a recent decision of the Enlarged Board of Appeal of the 
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European Patent Office (the so-called “broccoli” and “tomato” cases, G 2/12 and G 2/13, respectively). 
The decision confirmed that “essentially biological processes” of crossing and selection remain excluded 
from patentability1. The decision further indicated that plant products were eligible for patenting, if 
conforming to the normal conditions of novelty, inventiveness and applicability, even when the 
underlying methods are not under the EU Biotech Directive 98/44/EC.  
Industrial patenting in plants is common when it concerns genetically modified (GM) crops. Transgenic 
constructs can be relatively straightforwardly identified as inventions, while various techniques regarding 
plant transformation have been patented from the 1980s onwards. Indeed, at this date, the great 
majority (>90%) of patents regarding plants concern GM inventions. Possible effects of GM (transgenic) 
plant patents on accessibility of germplasm in Europe are small at this moment as very few GM crops 
made it into commercialisation due to explicit GM regulations. GM (transgenic) plant patents are outside 
the scope of this study.  
In the last decades, interest is rising in filing patent applications on products of conventional breeding as 
well (Louwaars et al. 2009). Here, inventiveness is based on the recognition, definition and/or 
combination of (gene variants underlying) traits into a useful trait in novel elite types of plants. Partly as 
distinction from GM traits, such traits have been named “native traits”, as they are, so to speak, natively 
(naturally) present in germplasm. Patenting of conventional breeding products has been stimulated by 
novel technology that led to higher investments in breeding research. This was particularly so with the 
advent of marker-assisted breeding (MAB). The use of DNA markers significantly increased the number 
of native traits that could be introduced into new plant varieties, and/or the speed by which native traits 
could be introduced or combined.  
The term “native traits” refers to traits already existing in germplasm, including wild relatives of crop 
species, or that can be produced by recombination of existing traits. Unfortunately, the term has not 
been defined exactly, and therefore stakeholders may have somewhat different views on what represents 
a native trait. In addition, it is a relatively recent term, up to now little used in the scientific literature 
and in patent filings. To our knowledge, no extensive public overview exists in scientific literature about 
the types of conventional breeding products and/or native traits that are the subject of patenting in 
practice, and the nature of the claims in these patents. There are some reports of collections and 
discussions of patents on conventional breeding by NGOs, e.g. Then & Tippe (2009, 2013, 2014) and 
Hammond (2011). Winnink (2012) recently provided an overview of numbers of plant breeding patent 
applications and companies/institutions involved, in which all types of biotechnology, including GM, were 
taken together.  
This report is a quick scan to explore “native traits” in relation to the parallel existence of the two main 
types of IPR in plant breeding in Europe. This exploration was performed by two approaches: 1) an 
exploratory inventory of European patents potentially addressing conventional breeding products, and 2) 
interviews with stakeholders about their experiences with and opinion about PBR and patents in relation 
to “native traits”. Clues provided by the interviews were used to focus the analysis of the patents on 
elements that could be relevant to the question of primary importance to breeders, namely, to what 
extent may patents involving native traits affect the use of genetic resources in breeding new plant 
varieties. We specifically looked at the following questions:  
 Can we estimate how many European patent applications involve conventional breeding products 
in plants? In searching for such patent applications, they need to be distinguished from patent 
applications involving genetic modification (i.e. referring to transgenic plants). Subsequently, we 
looked into the relevance of the patent applications found for“native traits”.  
 What types of traits and techniques, and in which crops, are the subject of these patent 
applications?  
 What sort of claims do we find in these patent applications?  
                                                            
 
1 “a process for the production of plants which is based on the sexual crossing of whole genomes and on 
the subsequent selection of plants, in which human intervention, including the provision of a technical 




 How is the “(native) trait” described and/or quantified and what may this mean for the efficiency 
by which they could be identified by breeders in plant material that they consider for use in a 
breeding programme leading to a commercial plant product?  
 Do the claims for conventional breeding products lead to specific questions with regard to the 
use of plant genetic resources in breeding?  
We performed this analysis on patent applications. It was not possible to do this on the same scale 
on granted patents as many patent applications are relatively recent and still in the examination 
phase. We note that there may be substantial differences between the claims in a patent application 
and those that are finally granted. In cases in which the patent has been granted, we could compare 
these, and where appropriate observations on differences are included.  
The scan was done in detail for patent applications found up to the end of 2013, more recent 
applications and granted patents will be briefly mentioned. It should be noted that the exact scope of 
claims can only be assessed in discussion with legal experts, and in the end may only be settled in 
court, but this was not part of this study. Hence, all numbers of patents and on traits in tables can 
only be taken as indicative. We touch upon GM traits with regard to their delimitation from native 
traits, but we do not address issues about GM (transgenic) crops themselves and their IP protection.  
In the interviews our focus was on the following topics:  
 How do stakeholders assess the impacts of patenting and PBR on “native traits” and what are in 
this context their opinions on the parallel existence of patenting and PBR?  
 What experiences do stakeholders have with concrete cases about access to and use of native 
traits in plants, and how could (possible) restrictions in this context be addressed?  
While this study was being carried out, there were ongoing societal discussions, such as on limited or 
broad breeders’ exemptions, and alternative solutions have been proposed and/or put in place by 
stakeholders to find the balance between innovation efforts and revenues, access to germplasm and 






The study consisted of two parts: exploration of patent applications and interviews with stakeholders. 
3.1. Exploration of patent applications on native traits 
Patent applications were searched using the database Orbit (Questel). The searches were limited to 
European patents (EP numbers). “Native traits” was not a common term or keyword in plant patent 
applications, even though a few applications did include the term as keyword. Underlying breeding 
methods would be a better starting point of this search, i.e. (in the context of PBR and patent 
discussions,) conventional techniques. A complicating factor is that for breeders in the European context, 
conventional methods usually refer to a series of techniques other than genetic modification (i.e. 
recombinant DNA technology/transgenic plants) that is under regulatory scrutiny of Directive 2001/18/EC 
(cf. van de Wiel et al. 2010). Some of these conventional techniques are of a more biotechnological 
nature than crossing and selection. Thus, mutagenesis and cell fusion (defined as genetic modification in 
the 2001/18/EC Directive, but specifically exempted from regulation) are classified with plant 
transformation in International Patent Classification under mutation or genetic engineering IPC codes 
C12N 15/01 and C12N 15/02, respectively (specifically C12N 15/05: plant cells). In addition, 
conventional methods of producing changes in chromosome number are coded separately as A01H 1/08 
under processes for modifying genotypes (mutagenesis has A01H 1/06, hybridisation and selection A01H 
1/02 and A01H1/04, respectively). On the other hand, crossing and selection are increasingly supported 
by (molecular/DNA) marker use (marker-assisted breeding or selection, MAB or MAS), which may be 
classified under C12N 15/09 (recombinant DNA technology). In addition, IPC codes appear not to be 
used consistently (see below).  
For obtaining an overview as comprehensive as possible for further discussion, we have in the first 
instance targeted patent applications not involving genetic modification/engineering sensu stricto (i.e. 
involving transgenic plants). After presenting the results, we will further discuss the relevance for “native 
traits”. Thus, IPC codes were used as follows:  
 A01H5+ (new plants: angiosperms) NOT C12N15/82 (genetic engineering with plant cells as hosts), 
to find patent applications involving plants but excluding those involving genetic engineering. The 
patent applications found were expected to cover conventional breeding methods and were therefore 
screened for their relevance to “native traits”. A part of them still proved to be based on genetic 
engineering/plant transformation, and these were removed. On the other hand, there are several 
reasons why this query did not completely cover patent applications related to conventional breeding:  
 A01H1+ (processes for modifying genotypes) may also contain claims on the products (i.e. plants) 
achieved by these processes. In particular claims on plants, and/or traits selected for, bear relevance 
to the question of the possible impact of IP protection on the use of genetic resources. Therefore, an 
additional search was performed with this IPC, excluding the above two categories.  
 The above excluded C12N15/82 (genetic engineering with plant cells as hosts) may in practice cover 
more than just GM sensu stricto, i.e. transformation of plants, for the following reasons:  
o Patent applications addressing characterized plant genes may claim both applications using GM 
(i.e. transformation) and applications using marker-assisted breeding or selection (MAB or 
MAS). MAB by itself can also be categorized under C12Q1/68 (tests involving nucleic acids). 
However, because of the large number of applications of such tests also in microorganisms and 
in medicinal technology, searches using this IPC produced an unmanageably large number of 
results. A feasible variant was a search with a combination of C12Q1/68 AND A01H1 OR 
A01H5, which, although in principle redundant compared to the above searches, did produce 
additional patent applications.  
o As mentioned, IPC codes appeared to be not always consistently attached to applications, i.e. 
C12N15/82 where C12Q1/68 would have been more applicable, or mutagenesis without code 
A01H 1/06 and/or C12N 15+ codes missing with mutagenesis.  
 An additional search using A01H4 (tissue culture, which is an important supporting technique in 
conventional plant breeding) did not yield additional patent applications. A search using A61K 
(medical preparations) did produce a few additional patent applications. 
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As a check whether patent applications with relevance to conventional breeding were missed, searches 
were also performed using specific breeding companies as term (list in Annex). Results were also cross-
checked with the ESA (European Seed Association) PINTO database (http://pinto.azurewebsites.net/). 
The PINTO database is a recent initiative that links marketed plant varieties to patents and patent 
applications. The database is filled by patent holders on a voluntary basis. The detailed search comprised 
patent applications up to the end of 2013. A less exhaustive search was performed for 2014 and 2015, 
which included the use of the patent listing of the recently established International Licensing Platform 
(ILF) Vegetable (see interviews and Discussion).  
Subsequently, the patent applications found were categorized based on crop species, breeding method 
and traits. Breeding methods encompassed basic crossing & selection, selection methods, modifying 
ploidy levels, etc. Traits involve for instance disease resistances, cytoplasmic or nuclear encoded male 
sterility (CMS or NMS), and more complex quality characteristics, such as shelf life (keeping quality). 
Claims were categorized according to the manner by which complex traits were described: 
morphological/plant architecture – qualitative (e.g. colour) or quantitative (e.g. internode lengths), 
physiological (e.g. hormonal tests), biochemical (e.g. levels of specific metabolites), and the genetic 
basis: locus (e.g. “classical” R gene-based disease resistance), QTL, gene, mutants, polygenic/not 
described. An attempt was made to distinguish between levels of precision in quantifying traits, e.g. 
absolute measures of quantities of a substance, or levels relative to those in a reference (breeders lines, 
plant line, known variety, deposited seeds).  
Patent applications were also followed in time, i.e. we noted dates of application and dates of granting, 
and dates of divisional applications when applicable. Published applications for patents were included 
since breeders may need to reckon with all claims as long as the patent is not finally granted. Indeed, 
patent applications not yet granted can also be found in the PINTO database mentioned above. For some 
claims with potential relevance to the use of genetic resources, such as whether more than one crop 
species was involved or with respect to the use of markers, we were able to compare the claims in the 
granted patent to those in the published application. In such cases we specifically noted claims that did 
not make it to a granted patent and/or for which a divisional application was filed. However, only a small 
number of patents has been granted so we only make a few qualitative observations by comparing the 
first published applications with the respective granted patents. Intermediate steps and the 
correspondence regarding claims during examination and/or opposition were not studied, as this study 
was meant as an exploration of a range of patent applications in this field, not as an in-depth study of 
particular patent applications.  
3.2. Interviews with stakeholders 
Interviews were carried out by Erik de Bakker and Clemens van de Wiel with seven stakeholders from 
the following fields: 
 Science (2) 
 Breeding companies (4) 
 NGO (1) 
The questionnaire used can be found in the Annex.  
Because the interviews were held in Dutch and the reports have been circulated for feed-back with the 




4.1. Exploration of patent applications 
The combined queries for patent applications produced approximately 400 European applications with an 
expected relevance to conventional breeding products up to 2013. In a less exhaustive search for 2014 
and 2015, 82 additional patent applications were found. The total number of applications for plant 
breeding innovations between 1980 and 2008 established by Winnink (2012) was 9456 through WIPO or 
EPO and 6106 through EPO exclusively. The applications included involved breeding methods counting as 
classical/conventional/traditional as opposed to genetic modification involving transgenic plants (e.g. Van 
de Wiel et al. 2010). Thus, applications referring to genes only counted when they were used in marker-
assisted breeding (MAB), i.e. in introgression by classical (“essentially biological”) methods of crossing 
and selection using DNA markers based on the gene sequences. In practice, such applications were often 
combined with use of the genes in GM, which made it more difficult to distinguish them from applications 
purely referring to GM. A small group combined GM traits with “native traits”, e.g. stacking of transgenes 
using conventional crossing or inducing infertility in GM plants by classical means (9 applications). Some 
techniques of a more biotechnological nature, such as protoplast fusion and mutagenesis, were included 
as the traits produced using these techniques are found in conventional (non-regulated) varieties which 
can be used by breeders as normal variation to be combined with other traits into new varieties using 
classical breeding techniques. Their relevance with regard to “native traits” will be discussed later on. 
Three applications found addressed oligonucleotide-directed mutagenesis, a novel genome editing 
technique with as yet an uncertain regulatory status with regard to genetic modification. These were not 
included in the analysis (for more details see the Discussion).  
We primarily focussed on claims on plants with specified traits as we were interested in possible effects 
of IP protection on accessibility of identifiable plant genetic resources. Often applications that primarily 
involved methods (process-based) for selection of specified traits, also contained a claim on plants; these 
were also included. However, process-based applications without direct claims on plants may still be 
relevant as to the traits themselves. This will be touched upon in the more detailed discussion below of 
claims. Using these criteria, 50 of the applications were process-based filings that apparently did not 
contain direct claims on plants and about 350 applications remained that contained claims on plants. 
Because of time limitations, 200 of these were studied in more detail. The primary focus of this subset 
was on applications in crops that are important to the Dutch breeding industry, i.e. vegetable crops, 
tomato, pepper, cucumber, melon/squash/watermelon, lettuce, potato, onion, leek, Brassica spp., also 
including the smaller crops such as pea, carrot, eggplant, rucola, celery, cichorium, corn salad, radish, 
and strawberry. For Brassica spp., also some oilseed crop applications were included, as was the case for 
sunflower, mainly comprising a range of fatty acids traits. Likewise, examples of traits such as 
carbohydrate, protein and/or secondary metabolite compounds as well as resistances against abiotic and 
biotic stressors were included for maize, wheat, grasses, sugar beet, soybean and other crops. Finally, a 
few applications in ornamentals and pharmaceutical crops were included in the selection. In this way we 
aimed to encompass the diversity of traits as well as possible in the subset of 200 patent applications. 
Thus, notably, a number of patents in arable crops were not included in the analysis, and so the numbers 
below must be taken as indicative.  
4.2. Patent applications: types of crops and traits, and techniques 
The (crop) plant species occurring in the subset of 200 applications are shown in Table 1. Major arable 
and horticultural crops are represented, and a few ornamental species. In addition, a few medicinal crops 
were encountered. Among the arable crops, the cereals maize and wheat, the oilseed crops oilseed rape 
and sunflower, and the protein crop soybean are represented. There are fewer applications for sugar 
beet and potato, which may reflect the relatively later developments in the use of biotechnology and/or 
the higher complexity of breeding in these crops. Among the horticultural crops, the largest numbers of 
applications are for the vegetable crops lettuce, cucumber, pepper, tomato and Brassica oleracea 
(cabbage, cauliflower, broccoli etc.). These may reflect the large investments in biotechnology in 
vegetable crop breeding in the last twenty years, particularly in MAB (see below).  
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Table 1. Crop species in the 200 patent applications studied in more detail. 
Cultivation types  Product types  Crop species  Cultivar group  # 









































Other  plant (crop) species     10 




Table 2. Traits in the 200 patent applications studied in more detail. 
Trait types: 
assessment 
Trait types Detailed traits # 




Quality traits: morphology Architecture (new form, taste, yield) 4 
Colour vegetable 4 









Quality traits: compounds Protein 1 
Fatty acid composition 16 
Carbohydrates 5 
Sucrose 3 





Taste combination 4 




F1 hybrid variety production Cytoplasmic male sterility CMS 15 
Nuclear male sterility NMS 7 
Others such as incompatibility, 
heterosis, flower morphology 
8 
Quality traits: seedless fruits Parthenocarpy 14 
Quality traits: physiology Shelf life 9 
Physiological disorders 2 
Tissue culture 1 
Quality traits: processing Several traits 2 
Resistance biotic stress Viruses 12 
Bacteria 1 





Tolerance abiotic stress Drought/nutrient stress 4 
Resistance herbicides IMI, glyphosate 5 
Yield Yield 2 
 Combinations of traits Several traits 4 





The traits for which applications were found are presented in Table 2. A large group (48%) of patent 
applications involved traits related to product quality (output traits as opposed to the input traits related 
to cultivation). Among these are fatty acid composition in oilseeds and starch in cereals. In vegetables, 
levels of secondary metabolites, such as flavonoids, carotenoids and glucosinolates, were represented. 
Also combinations of metabolites and/or morphology improving taste were found. Quality traits relevant 
for the grower, such as improved harvesting efficiency, encompassed 5%. Other types were improved 
processing and shelf life characteristics. The few ornamental applications also addressed output traits, 
such as flower architecture and/or colour patterns.  
Furthermore, 30% concerned resistances against pathogens and pests. Resistant plants were often the 
result of more or less complex interspecific crossings. Most applications addressed viruses, fungi or 
oomycetes; some targeted insects. Only a few applications concerned abiotic challenges to plants, such 
as drought and nutrient deficiency, which only recently became popular breeding goals. Herbicide 
tolerance was also represented, mostly tolerance to imidazolinone herbicides attained by mutagenesis or 
selection of spontaneous mutants. Finally, some applications addressed plant architecture improved for 
ease of harvesting.  
Fifteen percent of the applications was comprised of traits useful for F1 hybrid variety production, 
particularly male sterility and/or matching fertility restorers, the most common form being cytoplasmic 
male sterility (CMS), which in some crops originates from a cell fusion with other species (e.g. the Ogura 
cytoplasm from radish into B. oleracea and B. napus).  
 
Table 3. Techniques in the 200 patent applications studied in more detail. 
Methods # Comments 
Breeding method 4  
Selected plants 10  
Crossing & selection 66  
MAB/QTL 74 Of which 42 QTL 
Polyploidization 3  
Mutagenesis 38 Of which 20 mutation 
detection by sequencing 
Somatic hybridization 5  
Total 200   
 
With regard to the breeding techniques used, most classical techniques (for an overview see Van de Wiel 
et al. 2010) were represented (Table 3): interspecific crossing including sophisticated methods such as 
embryo rescue, ploidy level manipulation, with either haploidization or polyploidization, and tissue 
culture-related methods. Also mutagenesis and cell fusion were represented. Techniques involving 
modifying chromosome sets, such as addition or substitution lines and translocation breeding, were 
rarely encountered. Such techniques (including ploidy manipulation) often involve (bio)technological 
treatments, different from classical crossing and selection.  
While a few patent applications focus on particular, apparently more difficult interspecific hybridizations 
(4 in Table 2), most applications relate to the introgression of a desired trait from exotic germplasm of 
the primary gene pool or another species from the secondary gene pool. Introgression of the desired trait 
can be difficult, also with regard to the removal of the accompanying linkage drag. A similar problem 
may also occur when combining particular traits from elite germplasm, such as taste and keeping quality, 
when they are genetically closely linked. This is reflected in the types of selection methods used; 74 
applications (37%) involved MAB and/or QTL (quantitative trait loci) (see Table 3). Also with part of the 
mutagenesis applications, molecular-genetic methods were used for mutation detection (e.g. sequencing, 
TILLING). A special variant of this use of biotechnology for introgression of desirable traits from other 
species is protoplast fusion (somatic hybridization, Table 3), which is mostly used for the introduction of 
cytoplasmic male sterility (CMS).   
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Table 4. Distribution over time of patent applications and patents granted (checked up to 2015) in five- 
and ten-year periods for the 200 patent applications studied in more detail. 
Periods Applications Granted Decades Applications Granted 
1983-1987 1 0    
1988-1992 4 3 1983-1992 5 3 
1993-1997 19 14a    
1998-2002 32 15b 1993-2002 51 29 
2003-2007 60 27c    
2008-2012 84 11d 2003-2012 144 38 
Total 200 65  200 65 
a) 2 revoked after opposition; b) 2 revoked after opposition, 1 opposition ongoing; c) 4 revoked after opposition; d) 1 revoked 
after opposition, 3 opposition ongoing 
4.3. Patent applications: development over time 
Table 4 shows the steady growth of the numbers of published applications and patents granted over the 
years, from the early 1980s up to 2012. In the first two decades, about three out of five published 
applications were granted. This proportion may be lower for the last decade, but it is difficult to predict 
how this proportion will be in the end, as recent applications may still be granted in the coming years. 
One case was found in which a patent was granted after 14 years.  
4.4. Patent applications: product or process-based 
Even though there is considerable variation among applications in the way claims are composed, a few 
general patterns could be discerned:  
 Applications primarily claiming plants with a specified set of traits (“product-based” (IPC A01H5) or 
“product-by-process”). These may be described phenotypically or genotypically, in the latter case by 
loci, associated molecular (DNA) markers, QTLs and/or genes. Frequently, reference is made to 
representative seed samples from the plants claimed or sometimes from the plants from which the 
traits originated. These concerned samples that were deposited as obliged at collections of one of the 
International Depository Authorities (IDA such as NCIMB, ATCC). Subsequently, additional claims may 
be listed:  
o The breeding method by which the plants were produced. This is not frequently done, which may 
be related to the exemption of classical crossing and selection methods from patentability 
(“essentially biological processes” in EU patent law). 
Alternatively, there may be other method claims: 
o Methods using the plants claimed, such as propagation, cultivation/harvesting/processing, 
producing hybrid varieties, performing further crossing for introgressing other elite traits or 
transformation, genotyping using DNA markers. 
 Applications primarily claiming a method to introduce a trait into (elite) plants (“process-based”, IPC 
A01H1). This encompasses a broad field, including marker-assisted breeding/QTL identification, 
mutagenesis, somatic hybridization. Subsequently, the products of the methods, the plants, are often 
claimed as well, as above, or as obtained or obtainable by the methods claimed.  
For this study, in the first instance the applications containing plant claims were analysed in more detail 
as we were interested in possible effects on the use of genetic resources. Process-based applications that 
targeted general breeding methods such as doubled haploids, often did not contain any claims referring 
to specific traits. Such applications were left out of the more detailed analysis. Other process-based 
applications referred to the selection of (combinations of) traits. These may not claim the traits as such, 
but for instance with claims on the use of MAB (see below the section on MAB/QTL), they may be 
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relevant for breeders working on these traits. However, such process-based applications will likely have 
no direct effect on the use of genetic resources and therefore were also no part of the detailed analysis. 
There are indications that in recent applications primarily involving plant (product-based) claims, 
separate method claims are disappearing. This may be partly related to simplify the application, e.g. to 
avoid having to file a divisional later to fulfil unity of invention (either process or product emphasis). At 
the same time, method circumscriptions are increasingly incorporated into the descriptions of traits of 
the plants claimed, where they serve as a circumscription enabling reproducing the production of the 
plant (product-by-process). This may be related to the patentability of plant products of an inventive 
nature despite the exception for “essentially biological processes” (methods of crossing and selection), as 
was recently confirmed in the decision on the interpretation of the exception for “essentially biological 
processes” in the broccoli/tomato cases by the EBA of the EPO. Comparing the last two decades, there 
appears to be a trend of a relatively higher number of product-based applications as compared to 
process-based applications (see Table I in annex). In some cases, process-based applications were 
changed into product-based patents during the examination procedure. In other cases involving gene 
sequences, method (process) claims both for use in MAB and for use in genetic modification 
(transformation) could be combined with product claims for the GM versions of the plants only. The latter 
could sometimes also be seen only in the granted patent, when in the application product claims were 
made both for MAB-based and GM-based versions of the plants.  
4.5. Patent applications: trait descriptions 
The claims varied widely in the way traits were described and the level of complexity in descriptions 
varied with the type of trait. For exploring which germplasm may contain proprietary traits, it is 
necessary to get a hold on the exactness of descriptions in order to be able to identify the trait 
unequivocally. There are various ways by which descriptions could be categorized in order to assess their 
levels of complexity. An obvious distinction is between phenotypic and genotypic descriptions. 
Phenotypic descriptions were (tentatively) categorized in three types (see Table 2 for the relationship 
with individual traits): 
(i) Traits related to biochemistry, i.e. desirable compounds (output traits) such as fatty acid or 
starch compositions or levels of sugars, vitamins, carotenoids, or glucosinolates. Applications 
quantified amounts of the desired component in terms of M/w or w/w (fresh or dry weight of e.g. 
fruits) or relatively to other components, e.g. % saturated of all fatty acids in oilseeds or ratios 
of different glucosinolates. Alternatively, levels were compared to those of a specified plant 
standard or a plant not having the trait/wild type, and/or reference was made to the seed 
deposits at an IDA.  
(ii) Traits related to plant architecture (morphology), such as head form of broccoli or branching 
patterns of an ornamental. Salient characteristics could be quantified, e.g. numbers of branches, 
leaf forms, internode lengths, colours with reference to standard colour charts or, as a last 
resort, a drawing or photograph.  
(iii) Traits related to plant physiology, such as resilience against “yellowing” or “hollow stem” or 
keeping quality/shelf life. These were usually described by performing tests, e.g. ethylene 
treatments with description of expected plant responses, or in the case of shelf life, periods of 
time (days, weeks) in which e.g. a fruit should keep a specified firmness or colour. Tolerance to 
abiotic stresses such as drought, also fell under this category. Finally, some common traits that 
were also assessed using testing, were included: male sterility (22 applications in Table 2), in 
most cases located on cytoplasmic (mitochondrial) genomes, and resistance to biotic stresses. A 
large part of the applications addressed resistances against pathogens and pests (a total of 59 in 
Table 2) and many of these were not described in quantitative terms in claims but often were in 
the method descriptions in the patents, e.g. using scales, particularly in the case of MAB/QTL 
(see below). Again, as with morphology and biochemistry, plant references were often applied in 
several ways.  
Genotypic descriptions varied with mode of inheritance and the way this was detected, which could be 
classified as follows: 
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(i) Traits with a polygenic or unknown inheritance.  
(ii) Traits based on one or more loci that follow Mendelian inheritance. Qualitative resistance to 
pathogens based on classical R genes is a common (dominant) example. 
(iii) Traits based on quantitative trait loci (QTL), in practice formulated as markers for parts of 
genetic linkage groups that were associated with a specific complex plant characteristic, such as 
yield. 
(iv) Traits based on specifically identified genes. 
(v) “Rest” categories were polyploidy and mutants. The mutants referred to molecular-genetically 
uncharacterized ones from phenotypic screens or mutagenesis. The basis of locus- or gene-
related traits usually is an allelic variant having one or more mutations compared to “wild type” 
plants. 
The complexity of genotypic and phenotypic descriptions did not correlate with each other. Traits that 
were complex from a phenotypic point of view could be based on relatively simple modes of inheritance, 
i.e. loci or genes. For instance, one mutated gene may confer conspicuously different growth habits or 
leaf morphology (e.g. indented vs straight), i.e. a trait complex in phenotypic descriptions. On the other 
hand, disease resistance, often bred through R genes/loci, could also be based on combinations of QTLs, 
thus more complex in the genotypic description. Table 5 represents an attempt to present numbers of 
descriptions in the two dimensions, phenotypic and genotypic. The descriptions are categorized 
phenotypically across the rows as to the type (biochemical, morphological or physiological) and to the 
extent that traits were quantified in the claims, either absolutely (levels of a substance, lengths of plant 
part(s)) or by comparison to a specified control plant (line) or to similar plants or wild types not having 
the trait. Across the columns, the mode of inheritance is categorized. The most difficult to assess based 
on the descriptions in the claims will be the cases where qualitative/semi-quantified descriptions were 
combined with polygenic/unknown or unspecified inheritance. These cases were relatively rare, however 
(9 of 54 in column “polygenic/unknown inheritance”). More commonly, semi-quantified/qualitative was 
combined with information on genes (13 of 28), loci (39 of 58) or QTL (24 of 42). The most 
straightforward genotypic category, genes identified encompassed about one eighth of the applications 
(28 of 200).  
Biochemical traits were mostly quantified as levels of specific compounds or levels relative to those of 
other compounds. In about two third of the cases, quantification was in terms of higher or lower than a 
specified percentage or a specified quantity, e.g. microgram per gram biomass (13 and 10, respectively 
out of 35 applications). The remainder compared levels to plants not having the trait or was semi-
quantified, usually with a reference to plants (seeds) deposited along with the patent application. Most of 
these applications were based on genes. Most of the morphological traits were quantified absolutely or in 
comparison to a specified plant line instead of plants not having the trait. There were also a few 
qualitative ones, but their determination may not need to be a problem with morphological traits such as 
flower colour. The morphological traits descriptions were based more on loci than on gene sequences. 
Most of the descriptions that may be relatively difficult to assess, were encountered with the 
physiological traits, i.e. those containing no specific genotypic information combined with tests that need 
to be performed in comparison to plants not having the traits or without specified references. Most were 
based on genes, loci or QTLs, and most of the qualitative ones comprised disease or pest resistances. 
Many of the resistances that were not further specified/quantified in the claims, were provided with 
detailed scoring methods and/or disease scales in the descriptions or examples of the patents. This could 
be of importance with e.g. QTLs as they may not produce the described phenotype in all genetic 
backgrounds. The special genotypic category with claims based on QTLs will be discussed separately in 
the section on marker-assisted breeding (MAB) below. 
Table 5 provides a very general idea of the sort of observations or tests that may be needed to assess 
the presence of proprietary traits. In order to obtain a more concrete idea of the sorts of observations or 
tests that may need to be performed, we will discuss the patent applications in two crop species, tomato 




Table 5. Phenotypic and genotypic circumscriptions of traits in the 200 patent applications studied in more detail. Numbers are number of patents; the total 
numbers add up to over 200 because some applications involve a combination of more than one type of trait circumscription. 








morphology quantified in absolute terms 1 5 1   11 1   19 
quantified compared to reference plant/line           1   1 
quantified compared to reference plant without traits or wild type 1 2     1     4 
semi-quantified without specified ref   1     1     2 
Qualitative   1     3     4 
Total 2 9 1 0 16 2 0 30 
biochemical/compounds 
quantified in absolute terms 
7 2 2 6 18     35 
quantified compared to reference plant/line   1           1 
quantified compared to reference plant without traits or wild type 1             1 
semi-quantified modified levels without specified ref 6   1         7 
no quantification               0 
Total 14 3 3 6 18 0 0 44 
physiological 
quantified in absolute terms 1 6 3 2 7     19 
quantified compared to reference plant/line     3 1 1     5 
quantified compared to reference plant without traits or wild type 2 1 6 2 3     14 
semi-quantified modified levels without specified ref* 1 1 15 1 3     21 
qualitative* 6 36 8 2 2 1 10 65 
Total 10 44 35 8 16 1 10 124 
phenotypes complex many traits     3         3 
methods (involving 
specific traits & plants) 
interspecific hybridization, etc. 
2 2   1 4     9 
Total Overall 28 58 42 15 54 3 10 210 
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4.6. Patent applications: examples of assessing traits – tomato and lettuce 
In the previous sections, a broad overview has been given of traits and the ways they were described. In 
order to obtain a more concrete idea about what traits a breeder may have to assess to screen 
germplasm for possible proprietary traits, we have compiled, from the 200 patent applications, the data 
regarding two example crops, namely tomato and lettuce.  
Assessing whether the use of a plant may be affected by a claimed invention will mean testing for the 
presence of the traits whenever new lines enter a breeding programme, which is something that 
breeding companies may do on a regular basis nowadays (see interviews). For tomato we analysed 25 
patent applications plus 3 applications for a wider array of crops that included tomato. Of these, 5 were 
granted by EPO, of which one was revoked and another lapsed, 4 were withdrawn and one refused. 
These 7 were excluded and the remaining 21 applications were examined for phenotypic and genotypic 
traits to be assessed and the plant material where traits originated from (Table IIa in the annex). 
Likewise, for lettuce we analysed 15 patent applications plus 4 applications for a wider array of crops that 
included lettuce (2 overlapping with tomato). Of these, 7 were granted by EPO, of which 3 were 
undergoing an opposition procedure and another expired, and 2 were withdrawn. The remaining 16 
applications were examined for phenotypic and genotypic traits to be assessed and the plant material 
where traits originated from (Table IIb in the annex).  
Many phenotypic traits will be part of basic measurements in normal breeding practice (except e.g. for 
metabolites or mechanical tests, and specific disease resistance assays). For 17 of the 21 applications 
“alive” in tomato and 7 of the 16 in lettuce, relatively efficient molecular (DNA) tests could be performed 
to trace traits claimed.  
As a first step for assessing any possible effect of patents on the use of public germplasm, we looked at 
the origins of the traits mentioned in the claims. A number of wild accessions were mentioned as origins, 
including some from genebank collections. In tomato, the most commonly used crossing populations 
used for introgression into elite material, involving wild parents Solanum pennellii LA716 and S. 
habrochaites LYC4, were derived from published research by Eshed & Zamir 1995 and Finkers et al. 
2007, respectively. In lettuce also a number of wild accessions were mentioned as origins of traits in the 
applications, including some from genebank collections, in particular from CGN. Among them are 
crossing populations with wild parents Lactuca virosa CGN04683 and L. saligna CGN05271 published by 
Eenink et al. (1982) and Jeuken et al. (2004), respectively. Also a number of wild accessions of L. 






4.7. Patent applications: the case of marker-assisted breeding (MAB) and 
quantitative trait loci (QTL) 
About forty percent of the patent applications analysed encompassed marker-assisted breeding (MAB), 
i.e. selection for and introgression of desirable traits with the aid of molecular (DNA) markers genetically 
linked to loci of interest (74 of 200, see Table 3). Here too, descriptions of claims vary widely, from 
simply the use of MAB in the first applications of the late 1990s to detailed descriptions of markers used 
and positions on genetic linkage maps in more recent applications. Many of these applications address 
disease resistances.  
A special case is the introgression of so-called quantitative trait loci (QTL) enabled by MAB (42 of the 74 
MAB applications mentioned above). QTL refer to regions on a genetic linkage map that show a statistical 
association with the occurrence of a particular phenotypic trait, such as higher yield or a quantitative 
disease resistance. QTLs can be described using several aspects. Basically, one can specify one or more 
mapped markers associated with the trait to be selected for. This may also be termed a marker ‘linked 
to’ or ‘flanking’ a trait, or the trait may be ‘indicated by the presence of a marker. In some cases other 
markers are associated with linkage drag and so they should be selected against in order to maintain 
existing qualities of the elite material to be bred. Further possible refinements included describing 
intervals flanked or enclosed by markers (chromosomal or genomic regions). Claims on sequences, in 
particular probes or primers, may be accompanied by homology specifications, such as percentage 
sequence identity (usually of the order of 70-90%). This may be necessary to include sequence variation 
without significant effect on the trait of interest but relevant to the molecular detection methods. All such 
marker claims are conditional upon association with the trait of interest. As these QTL applications are 





5. Interviews with stakeholders (in Dutch) 
Note: Because the interviews were held in Dutch and the reports were circulated for feedback with the 
interviewees in Dutch, this part of the report is in Dutch. The interviews were held in Spring 2013.  
In mei en juni 2013 zijn zeven interviews afgenomen met verschillende belanghebbenden uit de 
wetenschap (2), het bedrijfsleven (4) en de samenleving (1). In totaal is met 11 mensen gesproken (zie 
de bijlagen voor de vragenlijst en lijst van geïnterviewden). In deze (semi-gestructureerde) 
vraaggesprekken is uitvoerig ingegaan op de impact die de verschillende beschermingssystemen van 
octrooieren en het kwekersrecht hebben op de omgang met en toegang tot Native Traits, welke voor- en 
tegenargumenten worden gezien voor beide beschermingssystemen in het kader van duurzame innovatie 
(economisch, sociaal, ethisch), over juridische procedures en ervaringen en hoe het beste is om te gaan 
met de omgang en toegang tot Native Traits. In elk interview werd benadrukt dat het hier om een 
verkennende studie ging die zich louter beperkt tot de kwesties die spelen rond ‘Native Traits’ en dat de 
bredere discussie over de balans tussen octrooirecht en kwekersrecht buiten het bestek van dit 
onderzoek valt. In de praktijk bleek echter dat de materie van Native Traits zich moeilijk ‘apart’ liet 
bespreken (zie ook de conclusies). In dit hoofdstuk presenteren we onze bevindingen aan de hand van 
de verschillende clusters van onderwerpen zoals die in de gesprekken naar voren kwamen. 
5.1. Het begrip Native Traits 
Bij twee van de vier bedrijven (Syngenta en Royal Van Zanten) en bij Oxfam Novib, werd langer stil 
gestaan bij de term Native Traits: wat is hieronder te verstaan? Hoewel je Native Traits in simpele 
termen kunt typeren als veredelingswerk zonder knip- en plakwerk van biotechnologische aard, waarbij 
je bepaalde eigenschappen ‘vindt of ontdekt’ maar niet door menselijk ingrijpen ‘uitvindt’, is dit 
onderscheid volgens deze twee bedrijven in de praktijk soms lastig te maken. Men spreekt dan over een 
grijs gebied waarbij het een discussie is welk soort recht hier van toepassing is of zou behoren te zijn. 
Oxfam Novib benadrukt dat Native Traits van nature voorkomende eigenschappen zijn, die vaak door 
generaties van boeren door kruisen en selectie naar boven zijn gehaald, en die derhalve ook buiten elk 
octrooirecht zouden moeten vallen, ook wanneer deze met behulp van allerlei technologie worden 
gebruikt en toegepast om meer bruikbare landbouwgewassen te krijgen.  
5.2. Kwekersrecht of octrooirecht? 
Vanuit de wetenschappers wordt naar voren gebracht dat octrooieren vooral in het voordeel lijkt te zijn 
van grotere bedrijven, wat als nadeel kan hebben dat kennisvermeerdering op slot wordt gezet wanneer 
er monopolies worden uitgeoefend. De Ponti, mede sprekend vanuit zijn ervaring in het bedrijfsleven, is 
zonder meer een voorstander van het kwekersrecht omdat plantenveredeling volgens hem bestaat bij de 
gratie van access: kwekersrecht is “open source” intellectueel eigendom avant la lettre. Hij ziet bij 
bedrijven een neiging tot ‘flauwekul-octrooien’ en bovendien dat grote bedrijven kwekers in 
ontwikkelingslanden kunnen imponeren waardoor deze kwekers niet eens doorhebben welke ruimte ze 
hebben om met beschermd uitgangsmateriaal te werken. Koornneef ziet evenwel dat het kwekersrecht 
voor bedrijven die veel in veredeling investeren nadelen kan hebben. Voor hem is de vraag uiteindelijk 
niet zozeer kwekersrecht of octrooirecht, maar met welke vorm van bescherming het publieke belang het 
meest gediend is. Onder publiek belang is hier enerzijds te verstaan de boer en tuinder die goede zaden 
nodig heeft om goed en veilig voedsel te kunnen produceren, het proces van innovatie dat daarbij hoort 
en bescherming tegen kopiëren, anderzijds de consument die goedkoop en veilig voedsel wil hebben. 
Ook Oxfam Novib benadert de discussie kwekersrecht of octrooirecht vanuit een meer algemene vraag: 
welke vorm van bescherming is het meest rechtvaardig en houdt rekening met de “Farmers’ Rights” van 
boeren in ontwikkelingslanden. Het octrooirecht, en tot op zekere hoogte het kwekersrecht staan op 
gespannen voet met het recht van boeren (‘farmers’ rights’) om geproduceerde zaden te bewaren, 
hergebruiken, uitwisselen, en verkopen (International Treaty on Plant Genetic Resources for Food and 
Agriculture). Het UPOV verdrag over kwekersrecht biedt landen de keuze om een dergelijk recht 
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(Farmers’ Privilege) te respecteren dan wel in te perken, met name door boeren niet toe te staan om 
hun zaden te verkopen. 
Bij de bedrijven zien we verschillende opvattingen. Enza en Syngenta zien in de toekomst een grotere rol 
weggelegd voor octrooirecht, om er voor te zorgen dat veredelaars hun langjarige investeringen in 
innovatieve planteigenschappen kunnen voortzetten met uitzicht op een redelijk financieel rendement. 
Royal van Zanten en Rijk Zwaan blijven in de toekomst een belangrijke rol zien voor het kwekersrecht 
(vanwege toegankelijkheid en de overtuiging dat dit uiteindelijk beter werkt voor innovatie, het voorkomt 
ook verdere juridificering). Ondanks deze principiële voorkeur voor het kwekersrecht, staan ze er 
pragmatisch in: ook zij zullen, als het erop aankomt, meedoen met het aanvragen van octrooien om niet 
geblokkeerd te raken door octrooien van derden. 
De meningsverschillen over kwekersrecht of octrooirecht zijn voor een deel ook terug te voeren op de 
inschatting of percepties van (individuele) bedrijven in hoeverre de door introgressie verworven Native 
Traits (waaraan kosten en investeringen zijn verbonden) zich terugbetalen. Sommigen zijn van mening 
dat een optimale "first to market" strategie met rassen (op basis van kwekersrecht) de ‘return on 
investment’ voldoende borgt, anderen vinden dat de aanvullende revenuen via octrooieren hier beter 
werken. Deze percepties, zo kan men stellen, hangen weer samen met opvattingen over monopolies die 
innovaties zouden kunnen afremmen. Tegenstanders van het octrooieren van natuurlijke eigenschappen 
stellen dat een voor iedere teler belangrijke eigenschap zoals ziekteresistentie ("killer application"), die 
via introgressie is verworven en al snel tot 100% marktdekking leidt, bij het systeem van octrooieren tot 
onwenselijke monopolies zou kunnen leiden. Ook wijzen ze in dit verband op het ongewenste effect dat 
bij een groeiend aantal octrooien veredelingsbedrijven genoodzaakt zijn al het plantmateriaal van buiten 
op mogelijk geoctrooieerde eigenschappen te onderzoeken; dit zou dan allerlei extra kosten met zich 
meebrengen, vooral als de eigenschappen moeilijk te detecteren zijn of de scope van de claims moeilijk 
is vast te stellen. 
Voorstanders van octrooieren stellen dat octrooien een middel zijn om kennis, tegen een redelijke 
vergoeding, te kunnen delen. Monopolies zijn in de plantenveredeling volgens hen vrijwel niet mogelijk 
omdat de uiteenlopende markten en klimaatzones om een zeer gedifferentieerde genetische basis 
vragen; geen enkele veredelaar heeft die in z’n totaliteit. Het licenseren van innovatieve eigenschappen, 
maar dan wel op basis van meer vereenvoudigde procedures, zou in deze visie voor alle partijen 
voordelig kunnen werken. 
5.3. Ervaringen juridische procedures m.b.t. Native Traits 
Drie van de vier benaderde bedrijven hebben juridische procedures meegemaakt naar aanleiding van 
octrooiclaims en oppositie tegen claims. Het aantal juridische zaken waarvan melding gemaakt wordt, is 
echter relatief gering te noemen. Wel is hierbij op te merken dat oppositie tegen octrooiclaims vaak niet 
zonder succes is. 
Met name de respondenten van het bedrijf dat nog geen concrete ervaring hiermee had opgedaan (Royal 
van Zanten), spraken hun vrees en verwachting uit dat ook zij gedwongen zouden zijn om mee te gaan 
met de ‘octrooitrend’ en dus ook de inschakeling van meer juristen en advocaten. In het algemeen is er 
bij de bedrijven een besef dat een zekere juridificering van de veredelingspraktijk en een toenemend 
juridisch steekspel omtrent octrooien, onvermijdelijk zijn. Waar het kwekersrecht nog meer op de 
coöperatieve gedachte zit (grotere toegangsmogelijkheden tot uitgangsmateriaal voor alle kwekers), is 
het octrooirecht harder en zakelijker te noemen. 
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5.4. Derde wegen? 
5.4.1. E-licensing als bemiddelende weg naar open toegang tot octrooien 
Om de problematiek van toegang, die vooral voor kleinere bedrijven kan spelen, te ondervangen, is er 
door Syngenta een systeem van E-licensing (genaamd TraitAbility) geïntroduceerd.2 De filosofie achter 
dit systeem luidt: ‘Free access, but not access for free’. Het komt er kort gezegd op neer dat de 
deelnemers aan E-licensing toegang hebben tot de planten waarin de geoctrooieerde traits zitten, zodat 
ze ermee kunnen werken, maar dat het wel zo is dat er licenties moeten worden geregeld en royalties 
afgedragen op het moment dat een nieuw product commercieel wordt gemaakt waarin nog geldige 
geoctrooieerde onderdelen zitten. Daarnaast zou Syngenta graag industriële patent pools (‘licensing-
platforms’) realiseren. Deze zouden volgens Syngenta zowel kleinere als grotere bedrijven tot voordeel 
kunnen strekken omdat men snel en transparant met elkaar tot overeenkomst kan komen over het 
gebruik van Native Traits en niet steeds opnieuw in onderhandeling hoeft te gaan. In de periode van de 
interviews was het onduidelijk of een dergelijk licensing-platform niet op problemen zou stuiten, omdat 
andere bedrijven en ook de EU dit wellicht zouden kunnen zien als concurrentievervalsing. Maar 
inmiddels hebben een aantal groentezaadbedrijven een gezamenlijk (internationaal) licensing platform 
gerealiseerd (zie de laatste sectie van dit hoofdstuk)3. 
5.4.2. Reacties op het ‘bemiddelende alternatief’ van E-licensing 
De reacties op E-licensing liepen uiteen. ENZA, dat ook een systeem van E-licensing heeft, deelt de 
mening van Syngenta en geeft er ook sterk de voorkeur aan dat de industrie zelf regelingen/systemen 
opzet om de beschermingssystemen van kwekersrecht en octrooien goed te laten samengaan; dat wordt 
als meer praktisch gezien dan de oplossing zoeken in nieuwe regelgeving en wetten. 
Royal van Zanten en Rijk Zwaan zijn beiden in principiële zin voor het kwekersrecht vanwege de “open 
source”-vorm die deze biedt tot de genetische bronnen. Kwekersrecht is naar hun mening uiteindelijk de 
beste weg voor innovatieve ontwikkeling in veredeling (en het voorkomt verdere juridificering). Maar 
ondanks deze voorkeuren wijst Rijk Zwaan een oplossingsweg om een pragmatische balans te vinden 
tussen voldoende “open toegang” (tot genetische bronnen) en octrooirecht zeker niet af. Hier zou 
wellicht een derde partij, denk aan een instantie met deskundigen en verschillende vertegenwoordigers 
uit de branche die over partijen heen denkt, een mediërende rol kunnen spelen. Ook de politiek zou hier 
een rol kunnen spelen, maar dat kan lastig zijn vanwege de complexiteit van deze materie, en nieuwe 
regelgeving is vaak ook een heel moeizame weg. 
5.5. Conclusies uit de interviews 
 Bij Native Traits bestaan er zowel verschillende meningen over (i) de feiten (hier: de impact van 
de verschillende beschermingssystemen in de vorm van kwekersrecht of octrooien) als over (ii) 
de waarden/doelen die rond Native Traits het richtsnoer moeten vormen. Dit maakt het tot een 
lastig onderwerp. We zien ook dat betrokkenen verschillende frames hanteren om hun 
ervaringen en meningen in te kaderen. Waar voor een maatschappelijke organisatie als Oxfam 
Novib de context van ‘farmers rights’ essentieel is, kijken bedrijven vooral vanuit een 
markteconomisch perspectief. Echter ook binnen het frame van een markteconomisch 
perspectief kwamen variaties naar voren in hoe smal of breed men de discussie over Native 
Traits trekt.  
 Voor bedrijven is de voorkeur voor het ene of het andere beschermingssysteem verbonden met 
verwachtingen/percepties van de impact, met de positie die men in het economische 
krachtenveld inneemt, en met de visie ten aanzien van het eigen verdienmodel. Hoewel niet alle 
                                                            
 
2 Zie voor meer details de websites www.traitability.com en http://www3.syngenta.com/global/e-
licensing/en/e-licensing/Pages/home.aspx. 
3 International Licensing Platform (ILP) Vegetable gelanceerd 13 November 2014, Wageningen.  
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bedrijven even actief bezig zijn met Native Traits octrooiaanvragen, wordt ook bij de bedrijven 
die er momenteel nog relatief weinig mee bezig (zoals in de siersector) terdege beseft dat het 
een belangrijk onderwerp is dat grote impact kan/zal hebben op toekomstige activiteiten en 
ontwikkelingen in de zaadveredelingsindustrie. 
 Momenteel zijn er ‘derde wegen’ in ontwikkeling om octrooieren meer acceptabel/transparant te 
maken (het voorbeeld is hier E-licensing). Een aantal bedrijven zoeken hier naar een 
pragmatische oplossing. Ook bedrijven met een voorkeur voor het kwekersrecht lijken nu meer 
te zien in dergelijke pragmatische oplossingen. Voor een maatschappelijke organisatie als Oxfam 
Novib moet deze discussie dan wel een brede ingang hebben (waarin bv. ook 'farmers rights' 
een plek hebben). 
 De meest belangrijke conclusie is dat het onderwerp zich in alle gesprekken lastig liet afbakenen 
van bredere vraagstukken die spelen rond technologische innovatie, zoals kansen in 
ontwikkelingslanden en Noord-Zuid-problematiek, concurrentieverhoudingen en monopolisering. 
(Zie voor een recente studie naar de ethische en maatschappelijke vraagstukken rond 
intellectueel eigendom Timmerman 2013.) Ook deze interviewreeks waarin vier bedrijven zijn 
opgenomen, bevestigt wat in de eerdere verkennende interviews ook al naar voren kwam. 
Discussies over Native Traits worden ervaren als een onderdeel van een bredere discussie over 
octrooieren en biotechnologie. Het loskoppelen van de problemen van Native Traits van deze 
bredere discussie is met het oog op de beleving van deze discussie in de praktijk derhalve lastig. 
Bij de partijen die geneigd zijn de discussie breder trekken, kan dit zelfs geforceerd overkomen. 
Wil men alle belangrijke stakeholders betrekken bij de discussie rond Native Traits, dan lijkt het 
raadzaam dit bredere verband te erkennen. 
5.6. Algemene slotopmerking uit de interviews: wat is het algemene belang? 
Een aandachtspunt dat verhelderend is om de verschillende posities en standpunten die naar voren 
worden gebracht te kunnen begrijpen en plaatsen, zijn de verschillende wijzen waarop het ‘algemene 
belang’ kan worden omschreven of begrepen. Grofweg is hier een onderscheid te maken tussen ‘eerlijke 
verdiensten’, ‘eerlijke concurrentie’, ‘eerlijke verdeling’ en ‘voedselzekerheid (ook voor de toekomst)’. 
‘Eerlijke verdiensten’ houdt in dat bedrijven die in innovaties investeren hun investeringen ook 
terugbetaald zien door een zekere vorm van juridische bescherming. Anders zouden marktpartijen zeer 
geremd zijn om nog te innoveren. 
‘Eerlijke competitie’ houdt in dat alle bedrijven eerlijke kansen hebben om te concurreren en dat ervoor 
gewaakt moet worden dat bepaalde bedrijven vanuit een monopolie de markt bepalen. Monopolies 
kunnen innovaties afremmen vanwege bedrijfsbelangen. 
‘Eerlijke verdeling’ houdt in dat er rekening moet worden gehouden met de Noord-Zuid-problematiek, 
met ongelijke machtsverhoudingen waardoor de kans bestaat dat boeren en ondernemers in 
ontwikkelingslanden minder kansen hebben om hun natuurlijke bronnen voor hun eigen profijt te 
benutten en te gebruiken. 
Waar Syngenta het accent legt op het algemene belang van ‘eerlijke verdiensten’, wijst een 
maatschappelijke organisatie als Oxfam Novib vooral op een ‘eerlijke (mondiale) verdeling’. De andere 
partijen die zijn geïnterviewd nemen hier tussenposities in, waarbij voor de minder grote 
veredelingsbedrijven vooral ‘eerlijke competitie  een cruciaal punt is. 
‘Voedselzekerheid (ook voor de toekomst)’ kan tenslotte worden gezien als een ‘gedeelde’ eindwaarde 
die door geen enkele partij ontkend zal worden, maar waarbij de meningen dus verschillen via welke weg 




This quick scan explores patent applications involving conventional breeding for the crops in which they 
were filed, the types of techniques and the traits involved. The aim of the quick scan was to facilitate 
discussions on the use of patents in conventional crop breeding in relation to the alternative IP system of 
PBR. Here we will first discuss views of stakeholders, mainly breeding companies, based on interviews. 
We then discuss how we collected published patent applications potentially relevant with regard to 
conventional breeding products. Subsequently, we looked into the relevance of the patent applications 
found for “native traits”. Based on the patent applications found and the claims they contain, we looked 
into several aspects of the question of what effects they may have on the use of germplasm for breeding.  
6.1. Views of stakeholders on native traits in relation to parallel existence of PBR and 
patent rights vary 
The interviews with stakeholders showed that breeding companies vary in their appreciation of the 
dilemma between adequate protection of IPR and facilitated access to genetic resources for future 
innovation in breeding. They all recognized that laborious introductions of native traits from exotic 
sources (e.g. wild species) into elite material while getting rid of linkage drag, demand high investments. 
In addition, a successful introgression of a highly desirable trait such as a disease resistance against a 
common pathogen can be seen as highly valuable (a “killer application”, i.e. it will quickly gain high 
market coverage). This also applies to varieties containing such trait. The choice for patent protection or 
PBR is dependent on the valuation of the effectiveness of recuperating the investment. Patent protection 
may effectively extend the protection beyond the commercial life span of individual varieties containing 
the proprietary trait. In these appraisals of the effectiveness of either IP system, modern marker-
assisted breeding (MAB) plays a more or less paradoxical role. On the one hand, it requires investments 
in the supporting DNA techniques, on the other hand it leads to more efficient selection, thus simplifying 
complex introgressions. Some companies argued that the fact that MAB can be used by their competitors 
to quickly introduce a novel introgression from a wild species into their own elite varieties, means that 
these competitors now can produce such competing varieties within a relatively short period of time. 
Other companies argue that such competition has always existed, and that the period in which the 
innovative variety has a large market share is still sufficient.  
Companies favouring patents for IP protection propose to address potential problems with access to plant 
genetic resources through e-licensing and/or patent pools, such as the recently established International 
Licensing Platform (ILP) Vegetable, in order to increase transparency on the patent claims attached to 
specific plants/seeds. In addition, the PINTO database initiative of ESA (European Seed Association) links 
patents to plant varieties marketed. The database is to be filled by patent assignees on a voluntary basis 
and up till now contains a limited number of patents. This is partly due to the focus on varieties, as only 
patents or patent applications are included that involve traits present in commercial varieties on the 
market. Also, not all companies have their patents or applications submitted to the database (yet). 
Indeed, these initiatives will assist breeders in identifying plants having proprietary traits produced by 
the patent holders themselves. The interviews namely also indicated that patents on native traits incited 
close scrutiny of new germplasm introduced into a company for the possible presence of any proprietary 
trait, which may come with additional costs. This will be further discussed in the next section.  
6.2. How to obtain a comprehensive overview of patent applications in conventional 
breeding? 
It proved to be not straightforward to obtain a comprehensive overview of patents involving native traits. 
Basic international patent classification codes could not be used by themselves as the codes for plant 
product and for process (A01H/5 and A01H1, respectively) include genetic modification (transgenic 
plants), and the number of patent applications involving genetic modification in plants is much larger 
than the number of patent applications regarding conventional breeding. Excluding genetic modification 
by using IPC code C12N15/82 (genetic engineering with plant cells as hosts) meant that a number of 
relevant patent applications were incorrectly excluded. Incorrect exclusion of patents was due to several 
reasons. An important reason was that applications involving genes may use them both for 
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transformation and for generating markers to be used in introgression (marker-assisted breeding, MAB, 
so classical crossing with selection supported by DNA markers). For assessing whether conventional 
breeding methods were involved could only be ascertained by scanning all claims of the application, and 
when this did not suffice, checking the methods used. A few special cases combined transgenic and 
native traits or selected for native traits improving transformability or improving expression of 
transgenes. In addition, IPC codes appeared to be not always used consistently. For instance, the 
C12N15/82 code was sometimes also used with mainly MAB-related patents whereas the C12Q1/68 code 
(tests involving nucleic acids) would have been more appropriate.  
In order to assess whether we had not missed patent applications, we additionally scanned patent 
applications from companies that we knew to be active in breeding. As this list of companies may not 
have been exhaustive, we still may have missed some patents here. For breeders it may be easier to 
obtain a comprehensive overview of relevant patented traits, as their searches would likely be targeted 
to a specific crop species, although it may take some effort to identify the patents and patent 
applications involving “native traits” in crops in which many patent applications, including those on GM, 
exist, e.g. in maize or to a lesser extent in a large vegetable crop such as tomato. In addition, some 
process-based patent applications may target a large number of crop species, e.g. ones focussing on 
desirable alleles of a gene that is universally present across plant species and for which it is not 
immediately apparent which particular crops may be involved. However, patent claims across crop 
species were only infrequently found in the final granted version of the patent; often, divisional 
applications were filed in such situations.  
Patent searches and assessments form a special expertise that innovative (bio)technological companies, 
including small ones, are used to invest in. However, they are relatively new to breeders used to PBR and 
may add costs for assessing material for proprietary traits, as mentioned in the previous section. Small 
breeding companies could decide to outsource patent searches to specialized agencies, in particular 
patent agents. Alternatively, they could co-operate with other small parties to share costs of patent 
watches. It is difficult to estimate the accompanying costs, amongst others because part of assessments 
for the presence of proprietary traits will belong to the routine screening of germplasm for breeding 
programmes (see also section 7.4 below). Other possible contributions to more transparency are the e-
licensing and/or patent pools mentioned in the previous section.  
Finally, it should be noted that patents may also be attractive to small (biotechnological) start-ups in 
breeding, in order to protect their position when they have not yet developed marketable varieties, and 
to research institutes to valorise their (pre)breeding research results when they are not developing 
varieties themselves, or to be able to optimize the use of the invention, which includes controlling as well 
as stimulating usage.  
6.3. What sort of patent applications involving conventional breeding can be found? 
From the point of view of the normal practice of using all available germplasm not under GM regulations 
in further breeding, all patents involving conventional breeding may play a role in discussions on IP 
protection, as can be seen in the sort of patents present in the collections in the PINTO database and the 
International Licensing Platform. Although this may not be immediately apparent from the traits of the 
products involved, not all such patents could be simply said to comprise “native traits”. Native traits can 
be defined as traits that occur in nature (i.e., in the germplasm of a plant species or genus), and they 
could thus be associated with those traits introduced or (re)combined by crossing and selection, i.e. 
“essentially biological” processes that are excluded from patentability in the European Patent Convention. 
However, traits occurring in nature could also be (re)combined by techniques of a more biotechnological 
nature, for instance, cell fusion (somatic hybridization), which can lead to novel combinations of 
cytoplasmic and nuclear genomes. Cell fusion may enable interspecific hybridizations, and thus produce 
combinations of traits that are hard to achieve by other means. Products of cell fusion are exempted 
from regulation of genetic engineering in EU Directive 2001/18/EC, provided that they could also be 
achieved using alternative conventional techniques of crossing and selection. However, this concerns the 
introduction into the environment, and does not address IP issues. Even when the traits have been 
introduced by crossing and selection, techniques of a biotechnological nature can play a role: complex 
interspecific crosses sometimes can only succeed by techniques such as “embryo rescue”, i.e. cultivating 
the hybrid embryo separated from the plant on artificial media. So, products and traits from advanced 
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conventional breeding methods may be indistinguishable from those from the most basic crossing and 
selection methods without detailed knowledge of the techniques used.  
Another case in which products (traits and their genetic basis) are in many cases indistinguishable from 
those that could be obtained by crossing and selecting among naturally occurring/spontaneous (“native”) 
variants in existing germplasm, is mutagenesis. Mutagenesis, which is used since the 1930’s, involves 
the random induction of mutations by agents of a technical nature, such as chemicals or irradiation, to 
increase the amount of genetic variation in existing germplasm. Selection of desirable genetic variation is 
performed as in normal screening and crossing in existing germplasm, and may need backcrossing with 
elite plant materials to remove other induced mutations affecting plant performance. The desired 
variation generated by mutagenesis can be novel, but may also occur somewhere in existing genetic 
resources. An example may be the dwarf growth habit in cereals that has been successfully generated 
using mutagenesis and applied in many varieties produced in the Green Revolution in the 1960’s. The 
dwarf growth habit is based on loss-of-function alleles in hormonal biosynthesis pathways (gibberellins). 
Recently, “green revolution” mutations have been found in natural populations of Arabidopsis thaliana 
(Barboza et al. 2013), implying that novelties may already exist in nature, but may be very difficult to 
find. Comparable cases are modifications of ploidy levels, addition/substitution lines and translocation 
breeding, as they are generally inducing or accelerating phenomena that also may occur spontaneously.  
Transgenic plants (not part of this quick scan) remain the most clearly recognizable category, as the 
transgenic construct is clearly recognizable as a human invention as it is an artificial combination of DNA 
sequences. That distinction may be complicated by the new breeding concept of cisgenesis where traits 
from cross-compatible plant species (i.e. species with which classical crossing and selection is basically 
possible) are introduced using transformation (Jacobsen & Schouten 2007). In this case, only the new 
location of the cisgene in the genome, and a small part of border sequences around it, remain features 
that distinguish the trait in a cisgenic variety from native forms in the germplasm. 
Recently, novel genome editing techniques, such as oligonucleotide-directed mutagenesis and zinc finger 
nucleases have been developed, for which a few patents were encountered as side-product of our patent 
searches. It is likely that more could be found with a targeted search. The number of patent applications 
for these techniques is expected to increase in the near future as a result of the quickly increasing use of 
the CRISPR-Cas variant of genome editing (Bortesi & Fischer 2015). Genome editing may be used for 
directional mutations, i.e. non-randomly altered nucleotide sequences at specific sites according to the 
investigator’s design. Directional changes in the genome are deemed eligible for patenting as not falling 
under the exemption of “essentially biological processes” by the Decision by the Enlarged Board of 
Appeal of the European Patent Office of 9 December 2010 in the consolidated cases, “broccoli” and 
“tomato”, G 2/07 and G 1/08, respectively. At the same time, without prior knowledge of their origin, the 
directional mutations may be indistinguishable from spontaneous mutations or those generated by 
mutagenesis. 
In conclusion, techniques that are eligible for patenting with regard to the exclusion of essentially 
biological processes, can lead to plant products that without prior knowledge, may be indistinguishable 
from those from crossing and selection, using genetic resources of the crop as source of the trait. Yet, 
the methods by which they were made may differ significantly in the underlying degree of 
biotechnological interventions. Thus, the natural occurrence of a particular trait may not preclude the 
possibility of patenting of novelties integrated into elite plant materials. Taken together, this may 
complicate the use of a concept of“native traits” in a discussion on (delimitation of) patentability in 
breeding, also in the light of continuous developments with the ongoing introduction of new 
biotechnological methods.  
6.4. May there be effects of patented traits on the use of publicly available 
germplasm? 
The genetic resources for which usage may be affected by a patent involving particular native traits, can 
be broadly divided into two types of germplasm:  
(i) varieties marketed by the breeder/patent holder (or their progenies) that contain the traits involved 
in the plant claims in the respective patent. This situation appears to become more transparent 
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because of actions of breeding companies, e.g. e-licensing and patent pools, such as the ILP 
Vegetable (International Licencing Platform Vegetable). An interesting example of increased 
transparency is ESA’s PINTO database coupling varieties to patents. There is as of yet a limited 
number of patents represented in this database (28 in the most recent update on 01-07-2015);  
(ii) all other varieties, breeding lines, and accessions that may possibly contain the trait described in the 
patents claims, e.g. by being identical to or by common ancestry with the plants used as source for 
breeding the plants under (i), or an alternative source of the trait (e.g. a genebank accession). 
Use of category (ii) plants or their progeny cannot be directly affected by claims on traits as the traits 
were already present in the material before the invention and thus have not been generated using the 
invention (Article 8 of Directive 98/44/EC). Could the descriptions laid down in claims on traits derived 
from e.g. genebank material affect in any way use of (parts of) this material in breeding for other traits? 
Genebanks are aware of this question around IP and access to resources as evidenced by distributing 
material under a Material Transfer Agreement containing an article about patenting and facilitated access 
to the plant material (see e.g. CGN: http://www.wageningenur.nl/en/article/Patents-on-native-
traits.htm). Many breeding programmes make use of publicly available germplasm, e.g. accessions from 
genebank collections, usually of older date. We discuss two observations that may have relevance to this 
question, namely on complex quantitative traits and QTLs. 
In patents, complex quantitative traits may be defined by physiological or biochemical tests. A 
physiological test applies for instance to reduced deterioration (e.g. yellowing) of plant products (keeping 
quality) or increased drought tolerance. A biochemical test could be the level of substances such as 
anthocyanins or glucosinolates. Quantitative traits may be laborious to assess when compared to a 
reference plant, such as a control plant without the trait, although there is always the possibility to refer 
to the seed deposits at an IDA. Such traits should be novel in elite plant material but might occur in 
other germplasm than the original or related accessions it was derived from, or in wild populations in 
situ. How many accessions might exist that already contain a level as has been claimed? What is the 
chance of this trait being introgressed along with breeding for other traits? In Brassica’s some vegetable 
types have been bred specifically with higher levels of particular glucosinolates, whereas some oilseeds 
have been bred for low levels of glucosinolates, including cases where these levels were part of linkage 
drag coming with the desired trait (e.g. fertility restorers for CMS). The range of such traits found in a 
wide array of genetic resources will not always be known.  
Introgressing desired traits is easiest if the allelic variants underlying the trait are known. However, most 
of the time the genes underlying desirable traits are not known or complex interactions between several 
genes may be responsible for the trait. A proxy is the QTL approach that detects a statistical association 
between markers for a part of the genome (chromosome) and a desired (native) trait. As compared to 
selection based on complex phenotyping, the advantage for the breeder is the possibility of efficient 
introduction of the trait by the markers whilst the same markers also enable to more precisely 
circumscribe/delimit the innovation in the patent. On the other hand, markers for a particular QTL may 
encompass an interval covering large parts of a chromosome. This is a consequence of the way QTLs are 
detected: the trait is statistically associated with a chromosomal interval, i.e. a specific part of a genetic 
linkage map flanked by particular markers, and the size of this interval and the statistical reliability (LOD 
score) may vary with the level of detail achieved by the availability of markers, the precision of 
phenotypic assessments (depending e.g. on field conditions and environmental variability), the number 
of progeny and the particular crossing parents used (e.g. Collard et al. 2005; Zhu et al. 2008; St.Clair 
2010). Except for special cases, QTL usually show partial contributions to the trait, i.e. they explain only 
a part of the variation in the trait found in the crossing population(s) studied. The causal genomic basis 
may be a yet unidentified gene but it may also be a combination of genes and/or gene-regulating factors 
residing in this part of the genome. Upon further research, a particular QTL might turn out to be based 
on the net effects of a combination of genes, which may even partially have contrasting effects on the 
phenotypic trait of interest (see for example Den Boer et al. 2013). Such QTL may have different effects 
when introgressed in other genetic backgrounds or under different environmental conditions. 
In the patent applications involving QTL, the phenotypic trait is claimed in combination with linked 
markers. Claims may involve various numbers of markers across the chromosomal interval associated 
with the QTL underlying a (native) trait, conditional on the presence of the proprietary trait. 
Chromosomal intervals may harbour large numbers of genes, and even hot spots, i.e. regions with QTLs 
for various types of traits, may be found in particular parts of genomes (e.g. Hartman et al. 2013). Thus, 
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it is conceivable that other desirable traits may be identified using a QTL approach in a region where a 
proprietary trait was already localized. One then may ask whether interference could occur. When for 
instance proprietary markers are detected in plant materials, when would one judge the associated 
proprietary phenotypic trait (QTL) to be absent? This will depend on the number of markers claimed and 
the exactness with which the trait is described, particularly in view of the usually quantitative nature of 
the trait and the variability of QTLs in various genetic backgrounds. Since QTL analysis is a relatively new 
topic in IPR, only few patents have yet been granted. 
The next-generation large-scale sequencing techniques may be helpful in obtaining more background 
knowledge for looking further into these questions around QTLs and use of germplasm. They are already 
being used for comparing genotypes of core collections of germplasm, including cultivated and wild 
accessions from genebanks, in important crops, such as tomato, a species that we used as an example 
on what sort of traits and markers one needs to screen to know whether a plant contains potentially 
proprietary traits/sequences. Compared to QTLs, gene sequences may be more straightforward in claims 
on the use of specific allelic sequences. In patents that include gene sequences, the claims may extend 
to a wide variety of crop species as many genes have homologues (orthologues) across a wide variety of 
higher plants in which comparable types of alleles with accompanying traits could be selected for. Claims 
on plants across wide groups of species were usually not granted in single patents, but separated into 
divisional applications (e.g. for each plant species or for different combinations of plant species and their 
pathogen). 
6.5. Final remarks 
IP protection systems exist in order to stimulate innovation, which creates important benefits for society. 
It is clear from the interviews we held, from the public discourse on this subject, and from the political 
debates on breeders’ exemptions, that stakeholders have different views on how to obtain suitable and 
sufficient IP for plant breeding when investments are rising. The concept of ‘native traits’ is an important 
one in these debates.  
Patent analysis is normal practice in technical innovation but relatively new in the field of plant breeding. 
Smaller companies will lag behind larger companies in building up the required expertise. The initiatives 
towards self-reporting of patent applications by breeding companies (PINTO database) address the issue 
of transparency, and other industry initiatives such as patent pools (e.g. ILP Vegetable), aimed at 
facilitating obtaining licences, also address the transparency of the legal situation. From the side of the 
civil society Patent Watch groups also contribute to transparency by analysing patent applications and 
fuelling a public discussion.  
The step beyond transparency is to determine the actual impact of the claims on breeding activities: 
what is restricted or needs a licence, and what is outside the invention and thus outside the scope of 
protection? This quick scan touched upon this subject, reasoning from biological/breeders knowledge. 
Notably, we asked ourselves whether patents involving quantitative characteristics and QTL may or may 
not affect the commercial use of gene bank accessions containing such traits. The answers to these 
questions will critically depend on the formulation of the claims, and how much room this leaves for 
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"D.J. van der Have" or "SESVanderHave" 
Hazera Seeds - Vilmorin & Cie 
HM. Clause - Vilmorin & Cie 
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Table I. Numbers of patent applications filed with primarily process-based claims and those with 















1983-1992 2 3 5 1 2 3 
1993-2002 22 29 51 12 17 29 
2003-2012 47 97 144 11 27 38 
Total 71 129 200 24 46 70 
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Table IIa. List of traits involved in patent claims to be assessed in tomato. 
Phenotypic:  
1. Morphological measurements on 
o Fruit size 
o Fruit colour 
o Fruit weight/plant 
o Sympodial index  
2. Physiological measurements 
o Leaf wilting assay (drought test) 
o Chlorosis by SPAD meter & yield (continuous light tolerance) 
3. Parthenocarpy 
o Assessing seedlessness of fruits 
4. Metabolites 
o Brix by refractometry 
o Flavonols by HPLC 
5. Shelf life 
o Timing of fruit keeping quality  
o Fruit wrinkling 
o Mechanical measurement of fruit firmness by penetrometer etc. 
6. Pathogen resistance assays 
o TOTV virus 
o TYLCV virus by field assay with infected whitefly 
o Botrytis 
o Phytophthora infestans 
o Meloidogyne nematode  
Genotypic:  
1. Gene expression 
1. >2 genes flavonol pathway 
2. Gene mutation sequence detection 
1. NOR gene 
2. SlARF9 gene 
3. SIPP2C1 gene 
4. SP3D & Psy1 genes (markers) 
5. HSK gene (no divisional application for tomato yet) 
6. DMR6 gene 
3. Loci by markers 
1. 1 on LG4 
2. 2 on LG6 
4. QTLs by markers 
1. 1 on LG9 
2. 5 (linked) on LG2 
3. 1 on LG4 LG5 LG12 resp 
4. 1 on LG1b LG6 LG9b resp 
5. 1 on LG4 LG6 LG9 LG11 LG12 resp 
6. 1 on LG4 
7. 1 on LG7 
5. Loci only assessable on progeny of crosses: 
1. 2 for parthenocarpy 
2. 7 unspecified mutants 
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Accessions of wild species from which introgressions have been derived: 
 Solanum habrochaites 
o 04TEP990312 (unknown origin 1 application)) 
o LYC4 (2 applications) 
o TA517 (1 application using L. hirsutum) 
 S. pennellii 
o LA716 (3 applications) 
o LA1926 (1 application) 
 S. chilense 
o LA2884 (1 application, same as LA1926) 
 S. lycopersicon var cerasiforme 
o LA1286 (1 application, same as LA1926 & 2884) 
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Table IIb. List of traits involved in patent claims to be assessed in lettuce. 
Phenotypic:  
1. Morphological measurements on 
1.1. Head colour 
1.2. Head leaf number/weight 
2. Physiological measurements 
2.1. Ethylene seedling test measuring hypocotyl length, optionally Russet spotting & Yellowing on 
mature plants 
3. Male sterility 
3.1. Assessing CMS 
3.2. Assessing NMS: detectable by flower heads remaining open longer & without pollen (Ms7) 
4. Shelf life 
4.1. Reduced discolouration at wound surface as compared to control plant of which leaf disc when 
incubated between two sheets of wetted filter paper for 7 days at 50C shows pink discolouration 
around the edges, optionally testing compounds involved in phenol oxidation (e.g. catechol) or 
inhibition by L-cysteine 
5. Pathogen resistance assays 
5.1. Oomycete Bremia lactucae (seedling and/or leaf disk tests, and/or field trials; 6 applications) 
5.2. Aphid Nasonovia ribis-nigri (assay on 2-4 wk old plants after 1-2 wks, 3 applications)  
Genotypic:  
6. Gene mutation sequence detection 
1. HSK gene 
2. DMR6 gene 
7. Loci/QTLs by markers 
1. 6 markers on 4 different LGs 
2. Marker linked to Ms7 
3. 1 QTL on LG8 
4. 1 QTL on LG2 & LG6, resp. 
5. Mitochondrial marker atp6 
8.  Loci only assessable on progeny of crosses: 
1. 3 for aphid resistance 
2. Unspecified mutants for reduced disease susceptibility 
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Accessions of wild species from which introgressions have been derived:  
Lactuca serriola 
 CGN05913 (IVT1308) 
 651554 (origin unknown, deposited as NCIMB 41488) 
 651738 (origin unknown) 




 CGN05315 (IVT1306) 
 650147 (origin unknown, deposited as NCIMB 41485) 
 650219 (origin unknown, deposited as NCIMB 41486) 
L. virosa 
 CGN04683 (IVT280) 
 CGN05148 (IVT1538) 
 CGN09365 (IVT1398) 
 PIVT-280 (CGN04683) & PIVT-cd72723 > IVT 793202 introgression line released 1981 
 651968 (origin unknown, deposited as NCIMB 41489) 
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List of interview questions 
1. Are you familiar with the debate about the impacts of the protection of intellectual property 
through patents and/or breeders’ rights on access to and use of native traits in plants? 
 
2. What are according to you the impacts of the protection of intellectual property through patents 
and/or breeders’ rights based on native traits in plants on access to and use of germplasm for 
breeding? 
 
3. Are you in favour of using patents or breeders’ rights for the protection of intellectual property in 
the context of access to and use of native traits in plants? 
a. What are your arguments for that position? 
i. What are the pros and cons of either protection method? 
ii. What is the importance of arguments about appropriate revenues sustaining 
innovation, including economic, social and ethical values? 
b. If it depends on the situation/trait/crop, when would patents be preferred and when are 
breeders’ rights to be preferred? 
 
4. Are you aware of any concrete cases of problems about access to and use of native traits in 
plants? 
a. (legal) disputes about claims 
b. (legal) disputes about infringements 
c. Uncertainty about the scope of claims on “native traits” impacting decisions about the 
use of particular plant materials 
d. Did you ever experience difficulties in access to genetic resources yourself? 
 
5. When access to and use of native traits in plants are restricted, how could these restrictions be 
addressed? 
 
6. If needed, what kind of changes do you propose to the protection of intellectual property 
through patents and/or breeders’ rights on access to and use of native traits in plants? 
a. Do these revisions address changes in patent law/directives or in their interpretation or 
additional arrangements within the breeding sector? 
b. Do these revisions primarily call upon action from public or private actors? 
c. Do these revisions require additional knowledge on (trends in) the types of claims in 
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Maarten Koornneef (em. Hoogleraar Erfelijkheidsleer Wageningen University & directeur Max Planck 
Institute for Plant Breeding Research) 
Orlando de Ponti (voor pensionering Directeur Onderzoek bij Nunhems, daarvoor directeur IPO 
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Rijk Zwaan: Jack de Wit (business support R&D) & Kevin van den Hof (innovation specialist R&D)  
Royal Van Zanten: Arie Veldhuyzen van Zanten (divisiedirecteur) & Sjoukje Heimovaara (directeur R&D) 
Syngenta: Gerard Meijerink (senior government relations advocate) & Leo Melchers (global head 
licensing) 
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